Merck, known as MSD outside the United States and Canada, today announced that the US Food and Drug Administration (FDA) has accepted for review supplemental New Drug Applications (sNDAs) for
Original Article: US FDA accepts for review Merck's sNDAs for Pifeltroand Delstrigo